RVX Share Price

Open 1.90 Change Price %
High 1.90 1 Day -0.02 -1.06
Low 1.83 1 Week 0.01 0.54
Close 1.87 1 Month 0.17 10.00
Volume 33402 1 Year 0.48 34.53
52 Week High 2.47
52 Week Low 1.10
RVX Important Levels
Resistance 2 1.93
Resistance 1 1.91
Pivot 1.87
Support 1 1.83
Support 2 1.81
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
IVN 4.97 2.26%
KAT 0.61 27.08%
KAT 0.61 27.08%
YRI 3.90 -3.47%
More..
TSE Canada Top Gainers Stocks
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
TVI 0.02 100.00%
KAT 0.61 27.08%
KAT 0.61 27.08%
PWC 0.10 25.00%
PWC 0.10 25.00%
IMP 0.11 22.22%
IMP 0.11 22.22%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
CTU-A 0.19 -9.52%
RKN 1.40 -8.50%
RKN 1.40 -8.50%
BUI 4.52 -7.76%
BUI 4.52 -7.76%
BUI 4.52 -7.76%
RIC 11.25 -7.71%
RIC 11.25 -7.71%
RIC 11.25 -7.71%
More..

Resverlogix Corp (TSE: RVX)

RVX Technical Analysis 3
As on 21st Feb 2017 RVX Share Price closed @ 1.87 and we RECOMMEND Buy for LONG-TERM with Stoploss of 1.54 & Buy for SHORT-TERM with Stoploss of 1.80 we also expect STOCK to react on Following IMPORTANT LEVELS.
RVX Target for February
1st Target up-side 2.45
2nd Target up-side 2.74
3rd Target up-side 3.02
1st Target down-side 1.65
2nd Target down-side 1.36
3rd Target down-side 1.08
RVX Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.resverlogix.com
RVX Address
RVX
279 Midpark Way S.E.
Suite 202
Calgary, AB T2X 1M2
Canada
Phone: 403-254-9252
Fax: 403-256-8495
RVX Latest News
Epigenetics: Cancer and Beyond   The New York Academy of Sciences   - 08th Jul 16
Zenith lands dough for bro, moves its lead cancer program into the clinic   BioWorld Online   - 18th May 16
3 Biotechs Getting a Second Chance After Failed Trials   Equities.com   - 07th Apr 16
Resverlogix: RVX-208 And The Epigenetics Of Age-Related Diseases   Seeking Alpha   - 28th Jan 16
What Students Struggle With Most When Analyzing Stocks in the Biotech Space   Equities.com   - 21st Jan 16
Resverlogix in Discussions to Be Bought, CEO Says   Bloomberg   - 28th Apr 15
Resverlogix: Analysis Of The Science Behind RVX-208   Seeking Alpha   - 08th Apr 15
Resverlogix Presents at Biotech Showcase During JP Morgan Week   Canada NewsWire (press release)   - 15th Jan 15
Resverlogix ASSERT Trial Data Illustrates Potential for RVX-208 in Alzheimer's ...   PR Newswire (press release)   - 25th Jan 11
Arthur J. Higgins, CEO of Bayer HealthCare, Appointed to Resverlogix Board of ...   PR Newswire (press release)   - 01st Feb 10
Interactive Technical Analysis Chart Resverlogix Corp ( RVX TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Resverlogix Corp
RVX Business Profile
Resverlogix Corp., a clinical stage cardiovascular company, develops compounds, which include a therapeutic increase in Apolipoprotein A-I. It primarily develops RVX-208, a small molecule that has completed a Phase IIb clinical trial SUSTAIN and is undergoing a second Phase IIb trial ASSURE for the treatment of atherosclerosis and other chronic diseases, such as neurodegenerative disorders, diabetes mellitus, and Alzheimer's disease. The company is headquartered in Calgary, Canada.